Provided by Tiger Trade Technology Pte. Ltd.

SELLAS Life Sciences Group Inc.

5.08
-0.2250-4.25%
Volume:333.17K
Turnover:1.70M
Market Cap:913.50M
PE:-20.60
High:5.14
Open:5.07
Low:5.04
Close:5.30
52wk High:6.14
52wk Low:0.9516
Shares:180.00M
Float Shares:179.00M
Volume Ratio:10.94
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2463
EPS(LYR):-0.2463
ROE:-66.88%
ROA:-34.74%
PB:12.89
PE(LYR):-20.60

Loading ...

SELLAS Life Sciences Stock Is Surging Higher: What's Going On?

Benzinga_recent_news
·
Dec 30, 2025

SELLAS Life Sciences Group Up Nearly 17%, on Track for Highest Close Since February 2023 -- Data Talk

Dow Jones
·
Dec 30, 2025

Sellas Life Sciences Says 72 Deaths Have Occurred in Phase 3 Acute Myeloid Leukemia Trial

MT Newswires Live
·
Dec 29, 2025

Sellas Life Sciences Reports Progress in Phase 3 REGAL Trial of Galinpepimut-S for AML

Reuters
·
Dec 29, 2025

Sellas Life Sciences Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (Gps) in Acute Myeloid Leukemia (Aml)

THOMSON REUTERS
·
Dec 29, 2025

New NASA Chief Vows: Moon Return Within Trump's Term

Stock News
·
Dec 28, 2025

Key Reasons Behind Jared Isaacman's Appointment as NASA Administrator and Analysis of the Athena Plan

Deep News
·
Dec 21, 2025

SELLAS Life Sciences Group (SLS): Valuation Check After Positive Phase 2 Data for SLS009 in AML

Simply Wall St.
·
Dec 10, 2025

Sellas Life Says Phase 2 Study of Cancer Combination Treatment Shows 'Clinically Meaningful' Activity; Shares Up Pre-Bell

MT Newswires Live
·
Dec 08, 2025

Sellas Life Sciences Announces Positive Phase 2 Results for SLS009 Combination in Relapsed AML

Reuters
·
Dec 08, 2025

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

GlobeNewswire
·
Dec 08, 2025

Director Katherine Bach Kalin Acquires Common Shares of Sellas Life Sciences Group Inc

Reuters
·
Nov 21, 2025

SELLAS Life Sciences Q3 Net Income USD -6.791 Million

Reuters
·
Nov 20, 2025

SELLAS Life Sciences Q3 net loss narrows to $6.8 mln

Reuters
·
Nov 13, 2025

BRIEF-SELLAS Life Sciences Q3 Net Income USD -6.791 Million

Reuters
·
Nov 13, 2025

Press Release: SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Nov 13, 2025

Sellas Life Sciences options imply 12.3% move in share price post-earnings

TIPRANKS
·
Nov 13, 2025

Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News

Benzinga_recent_news
·
Nov 11, 2025

Sellas Life Sciences Group Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Ero Announces Result of Year-Long Value-Creation Initiative at Xavantina, Commences First Gold Concentrate Sales in Q4 2025

GlobeNewswire
·
Nov 04, 2025